Press Releases

aTyr Pharma, Inc. a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present clinical and preclinical data for efzofitimod (ATYR1923), its lead therapeutic candidate, in three posters at the American Thoracic Society (ATS) 2022 International Conference, which is being held May 13 – 18, 2022, in San Francisco, CA. “The selection of three abstracts featuring da

BridgeBio Pharma, Inc.  a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced updated data from its ongoing Phase 2 open-label extension (OLE) study of acoramidis (AG10) in patients with symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). The results were featured in an oral presentation at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place in Washington, D.C. on April 2 – 4, 2022

Todos Medical, Ltd.  a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. is reporting a case study from a patient with Long COVID who was recommended Tollovid by their physician Dr. John Mabayoje, a family medicine physician based in Richmond, Maryland. ABSTRACT: Post-Acute Sequelae of SARS-CoV-2 (PASC), or Long COVID, is a major public health problem. We report a case

Rx Holdings, the parent company of InfinityRx and eScript360™, acquired Biocel Access Solutions, realizing the complete design, fulfillment, and delivery of Patient Service Programs that are sponsored by pharmaceutical manufacturers. Biocel Access Solutions is a consulting group that has served specialty, compounding, and home infusion pharmacies and is led by Richard (Rick) A. Ford, who is also the former Vice President of Market Access for Trialcard. Rick joins the executive

 Athira Pharma, Inc.  a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today issued the following statement in response to the release from Richard Kayne: Athira’s board and leadership team are focused on doing what is right for the company, our shareholders and patients. Athira’s highest priority is advancing fosgonimeton through clinical trials and securing regulatory

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that the company has been granted U.S. Patent No. 11,167,003 entitled: “Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems.” GA Depot is a long-actin

SynShark and Phylloceuticals have announced the formation of a strategic partnership that is likely to change the way squalene, a critical immunologic adjuvant, is manufactured in the future. Phylloceuticals is a leader in plant-based pharmaceutical manufacturing, with a mission to supply underserved world markets to gain access to needed medicine. SynShark was founded to find new manufacturing platforms to replace or replenish currently unsustainable resources such as squalene. Jason Ornstei

CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. Investing over $250 million in the project, the new 710,000 ft2 site will comprise one of the world’s largest single facilities for cell and gene therapy manufacturing and advanced stem cell biobanking. The construction of the state-of-art facility is expected to be completed by the end of 2024. Within the facility, the space dedicated for cell and gene the

Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), announced today that the companies are unveiling Xpert Alliance, a joint visualization of their strategic collaboration. The visualization is designed to “bring to life” this ongoing alliance and celebrate its successful operation, delivering effective solutions to address clients’ changing and expanding needs in the area of complex biopharmaceuticals.

ABIONYX Pharma , a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to the Bio-HDL CER-001 for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiency. The designation covers both partial LCAT deficiency, presenting as Fisheye Disease, and complete LCAT deficiency presenting with renal symptoms and corneal opa